Diamond-Blackfan anemia 17
diseaseOn this page
Also known as DBA17
Summary
Diamond-Blackfan anemia 17 (MONDO:0044310) is a disease with 1 cohort gene.
At a glance
- Cohort genes: 1
- ClinVar variants: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Diamond-Blackfan anemia 17 |
| Mondo ID | MONDO:0044310 |
| OMIM | 617409 |
| DOID | DOID:0111880 |
| UMLS | C4479428 |
| MedGen | 1373199 |
| GARD | 0016228 |
| Is cancer (heuristic) | no |
Also known as: DBA17 · Diamond-Blackfan anemia 17
Data availability: 2 ClinVar variants · 2 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › pure red-cell aplasia › Diamond-Blackfan anemia › Diamond-Blackfan anemia 17
Related subtypes (21): Diamond-Blackfan anemia 1, Diamond-Blackfan anemia 14 with mandibulofacial dysostosis, Diamond-Blackfan anemia 2, Diamond-Blackfan anemia 15 with mandibulofacial dysostosis, Diamond-Blackfan anemia 3, Diamond-Blackfan anemia 4, Diamond-Blackfan anemia 5, Diamond-Blackfan anemia 6, Diamond-Blackfan anemia 7, Diamond-Blackfan anemia 8, Diamond-Blackfan anemia 9, Diamond-Blackfan anemia 10, Diamond-Blackfan anemia 11, Diamond-Blackfan anemia 12, Diamond-Blackfan anemia 13, Diamond-Blackfan anemia 21, Diamond-Blackfan anemia 18, Diamond-Blackfan anemia 19, Diamond-Blackfan anemia 20, Diamond-Blackfan anemia 16, Diamond-Blackfan anemia 22
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
2 retrieved; paginated sample, class counts are floors:
1 benign, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 417765 | NM_001030.6(RPS27):c.90del (p.Tyr31fs) | LOC126805872 | Pathogenic | no assertion criteria provided |
| 1327974 | NM_001030.6(RPS27):c.116-45_116-44dup | LOC126805872 | Benign | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 2 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| RPS27 | Limited | Unknown | Diamond-Blackfan anemia 17 | 2 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| RPS27 | Orphanet:124 | Diamond-Blackfan anemia |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| RPS27 | HGNC:10416 | ENSG00000177954 | P42677 | Small ribosomal subunit protein eS27 | gencc |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| RPS27 | Small ribosomal subunit protein eS27 | Component of the small ribosomal subunit. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| RPS27 | Other/Unknown | no | Ribosomal_eS27, Ribosomal_zn-bd, Ribosomal_eS27_Zn-bd_dom_sf |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| ganglionic eminence | 1 |
| granulocyte | 1 |
| lymph node | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| RPS27 | 134 | ubiquitous | marker | ganglionic eminence, granulocyte, lymph node |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| RPS27 | 3,809 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| RPS27 | P42677 | 214 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 68. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Eukaryotic Translation Initiation | 1 | 308.6× | 0.018 | RPS27 |
| Cap-dependent Translation Initiation | 1 | 308.6× | 0.018 | RPS27 |
| SARS-CoV-1 modulates host translation machinery | 1 | 308.6× | 0.018 | RPS27 |
| Eukaryotic Translation Elongation | 1 | 278.5× | 0.018 | RPS27 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 1 | 271.9× | 0.018 | RPS27 |
| Nonsense-Mediated Decay (NMD) | 1 | 233.1× | 0.018 | RPS27 |
| SARS-CoV-2 modulates host translation machinery | 1 | 223.9× | 0.018 | RPS27 |
| Influenza Viral RNA Transcription and Replication | 1 | 215.5× | 0.018 | RPS27 |
| Formation of the ternary complex, and subsequently, the 43S complex | 1 | 215.5× | 0.018 | RPS27 |
| Amplification of signal from the kinetochores | 1 | 196.9× | 0.018 | RPS27 |
| Selenoamino acid metabolism | 1 | 196.9× | 0.018 | RPS27 |
| Translation initiation complex formation | 1 | 190.3× | 0.018 | RPS27 |
| Ribosomal scanning and start codon recognition | 1 | 190.3× | 0.018 | RPS27 |
| Influenza Infection | 1 | 175.7× | 0.018 | RPS27 |
| SARS-CoV-1-host interactions | 1 | 175.7× | 0.018 | RPS27 |
| Cellular response to starvation | 1 | 165.5× | 0.018 | RPS27 |
| rRNA processing in the nucleus and cytosol | 1 | 160.8× | 0.018 | RPS27 |
| Mitotic Spindle Checkpoint | 1 | 158.6× | 0.018 | RPS27 |
| rRNA processing | 1 | 146.4× | 0.018 | RPS27 |
| SARS-CoV-1 Infection | 1 | 142.8× | 0.018 | RPS27 |
| Peptide chain elongation | 1 | 126.9× | 0.018 | RPS27 |
| Viral mRNA Translation | 1 | 126.9× | 0.018 | RPS27 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | 1 | 125.5× | 0.018 | RPS27 |
| Signaling by ROBO receptors | 1 | 124.1× | 0.018 | RPS27 |
| Selenocysteine synthesis | 1 | 120.2× | 0.018 | RPS27 |
| Eukaryotic Translation Termination | 1 | 120.2× | 0.018 | RPS27 |
| SARS-CoV-2-host interactions | 1 | 119.0× | 0.018 | RPS27 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 1 | 117.7× | 0.018 | RPS27 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | 1 | 117.7× | 0.018 | RPS27 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 1 | 116.5× | 0.018 | RPS27 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| ribosomal small subunit assembly | 1 | 1404.3× | 0.004 | RPS27 |
| ribosomal small subunit biogenesis | 1 | 227.7× | 0.009 | RPS27 |
| cytoplasmic translation | 1 | 185.2× | 0.009 | RPS27 |
| rRNA processing | 1 | 141.6× | 0.009 | RPS27 |
| translation | 1 | 102.8× | 0.010 | RPS27 |
Therapeutics
Drug target analysis
Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| RPS27 | GENTAMICIN SULFATE |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| RPS27 | 1 | 4 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| GENTAMICIN SULFATE | 4 | RPS27 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| RPS27 | 97 | Binding:97 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| GENTAMICIN SULFATE | 4 | RPS27 |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 1 | RPS27 |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: RPS27